Truist Financial’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$51.1M Sell
114,449
-11,744
-9% -$5.48M 0.07% 240
2025
Q4
$57.2M Sell
126,193
-17,671
-12% -$7.62M 0.08% 223
2025
Q3
$56.3M Sell
143,864
-66,225
-32% -$27.7M 0.08% 222
2025
Q2
$93.5M Sell
210,089
-13,881
-6% -$6.4M 0.14% 148
2025
Q1
$109M Buy
223,970
+12,166
+6% +$5.67M 0.17% 130
2024
Q4
$85.3M Buy
211,804
+1,885
+0.9% +$874K 0.13% 145
2024
Q3
$97.6M Sell
209,919
-8,722
-4% -$4.19M 0.15% 130
2024
Q2
$102M Sell
218,641
-4,470
-2% -$1.94M 0.16% 136
2024
Q1
$93.3M Sell
223,111
-2,245
-1% -$949K 0.14% 146
2023
Q4
$91.7M Sell
225,356
-1,707
-0.8% -$631K 0.15% 139
2023
Q3
$79M Buy
227,063
+58,219
+34% +$20.4M 0.13% 157
2023
Q2
$59.4M Buy
168,844
+8,141
+5% +$2.74M 0.1% 194
2023
Q1
$50.6M Sell
160,703
-10,741
-6% -$3.22M 0.09% 217
2022
Q4
$49.5M Buy
171,444
+62,866
+58% +$19.2M 0.09% 212
2022
Q3
$31.4M Buy
108,578
+1,741
+2% +$501K 0.06% 280
2022
Q2
$30.1M Sell
106,837
-4,137
-4% -$1.11M 0.06% 305
2022
Q1
$29M Buy
110,974
+26,836
+32% +$6.37M 0.05% 332
2021
Q4
$18.5M Buy
84,138
+2,887
+4% +$561K 0.03% 453
2021
Q3
$14.7M Buy
81,251
+43,511
+115% +$8.5M 0.02% 502
2021
Q2
$7.61M Buy
37,740
+85
+0.2% +$17.8K 0.01% 730
2021
Q1
$8.09M Sell
37,655
-1,866
-5% -$410K 0.01% 673
2020
Q4
$9.34M Sell
39,521
-2,794
-7% -$641K 0.02% 619
2020
Q3
$11.5M Buy
42,315
+2,825
+7% +$779K 0.03% 516
2020
Q2
$11.5M Buy
39,490
+4,584
+13% +$1.24M 0.03% 500
2020
Q1
$8.31M Sell
34,906
-265
-0.8% -$60.8K 0.02% 550
2019
Q4
$7.7M Buy
35,171
+25,577
+267% +$5.18M 0.02% 638
2019
Q3
$1.63M Buy
9,594
+83
+0.9% +$14.7K 0.03% 386
2019
Q2
$1.75M Sell
9,511
-172
-2% -$30.1K 0.03% 373
2019
Q1
$1.78M Sell
9,683
-94
-1% -$17.4K 0.03% 367
2018
Q4
$1.62M Sell
9,777
-685
-7% -$119K 0.03% 369
2018
Q3
$2.02M Buy
10,462
+104
+1% +$18.5K 0.04% 364
2018
Q2
$1.76M Sell
10,358
-1,067
-9% -$165K 0.03% 378
2018
Q1
$1.86M Buy
11,425
+227
+2% +$37.1K 0.04% 374
2017
Q4
$1.68M Buy
11,198
+92
+0.8% +$13.6K 0.03% 398
2017
Q3
$1.69M Sell
11,106
-203
-2% -$30.6K 0.03% 381
2017
Q2
$1.46M Sell
11,309
-2,020
-15% -$243K 0.03% 403
2017
Q1
$1.46M Buy
13,329
+5,223
+64% +$460K 0.03% 413
2016
Q4
$597K Buy
8,106
+45
+0.6% +$3.66K 0.01% 558
2016
Q3
$703K Sell
8,061
-340
-4% -$32.1K 0.01% 530
2016
Q2
$723K Buy
8,401
+308
+4% +$26.6K 0.02% 530
2016
Q1
$644K Buy
8,093
+67
+0.8% +$6.06K 0.02% 503
2015
Q4
$1.01M Buy
8,026
+4,566
+132% +$551K 0.03% 413
2015
Q3
$360K Buy
3,460
+1,164
+51% +$150K 0.01% 624
2015
Q2
$284K Sell
2,296
-45
-2% -$5.67K 0.01% 669
2015
Q1
$276K Sell
2,341
-1,725
-42% -$207K 0.01% 684
2014
Q4
$483K Sell
4,066
-272
-6% -$30.6K 0.01% 519
2014
Q3
$487K Sell
4,338
-214
-5% -$20.4K 0.01% 501
2014
Q2
$431K Sell
4,552
-515
-10% -$36.1K 0.01% 543
2014
Q1
$358K Buy
5,067
+290
+6% +$23K 0.01% 583
2013
Q4
$355K Sell
4,777
-713
-13% -$49.7K 0.01% 584
2013
Q3
$416K Buy
5,490
+181
+3% +$14.4K 0.01% 526
2013
Q2
$425K Buy
+5,309
New +$391K 0.02% 513

Other funds holding VRTX

Truist Financial's VRTX Position: Q1 2026 in Review

Truist Financial reduced its Vertex Pharmaceuticals (VRTX) stake by 9.3% in Q1 2026, selling an estimated $5.48M and leaving 114,449 shares worth $51.1M. The position accounts for 0.07% of the portfolio, ranked #240.

Truist Financial first reported a position in VRTX in Q2 2013 and has held it in 52 quarters since. The position peaked at $109M in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Truist Financial held 114,449 shares of Vertex Pharmaceuticals worth $51.1M as of Q1 2026.
  • Truist Financial sold 11,744 Vertex Pharmaceuticals shares in Q1 2026, an estimated $5.48M.
  • Vertex Pharmaceuticals made up 0.07% of Truist Financial's portfolio in Q1 2026, its #240 holding.
  • Truist Financial first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Truist Financial's Vertex Pharmaceuticals position peaked at $109M in Q1 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Truist Financial's 13F filing for Q1 2026, filed 27 Apr 2026.